Back to today’s briefing

Story perspectives

STRIDE Immunotherapy Doubles 5-Year Survival for Liver Cancer

7/23/2025

46 3

Summary

Story summary

A groundbreaking study in the Journal of Hepatology shows that nearly 20% of patients with unresectable hepatocellular carcinoma (uHCC) survived five years after receiving the innovative STRIDE immunotherapy, a stark contrast to just 9.4% survival with sorafenib. This promising development brings renewed hope to patients and healthcare professionals alike.

1 of 1

Story summary

A groundbreaking study in the Journal of Hepatology shows that nearly 20% of patients with unresectable hepatocellular carcinoma (uHCC) survived five years after receiving the innovative STRIDE immunotherapy, a stark contrast to just 9.4% survival with sorafenib. This promising development brings renewed hope to patients and healthcare professionals alike.